Despite the vast progress in treatments delivered by Pharma, across multiple therapeutic areas, suboptimal patient outcomes in the real world setting remains a major concern for all stakeholders. Payers and empowered patients alike are demanding better clinical and economic outcomes that demonstrate value ‘beyond the pill’.
A logical place to start is by analysing the care pathway to identify where the outcomes from existing treatments are impaired. Companies need to understand how patients behave in the real world, as opposed to trial situations, from an emotional, physical and treatment- related perspective.
On May 21st, this webinar will examine how evidence-based patient pathway mapping can help Pharma companies understand when and how their drugs are used, in order uncover opportunities to maximise value across the care continuum.
The panel will explore how pathways should be
- Evaluated by overlaying multiple lenses: patient, payer, healthcare professionals, health system infrastructure and funding flows.
- Enhanced through partnerships with healthcare professionals. This may include help with secondary-primary care links and improving adherence.
- Amal Ismail, Director of Care of Pathway Solutions team at DHC, on how to evaluate pathways by overlaying multiple lenses (patient, payer, HCP, health system infrastructure and funding flows) to uncover new opportunities
- Antoine Lecourt, Global Marketing Director at GSK Oncology, on how to translate patient pathway insights into actionable strategies that enhance a brand’s value proposition
- Navin Joshi, Senior Director Market Access Capability at GSK, on how to build internal capabilities to support adoption and implementation of patient-centric solutions
- Alexandre Chan, Associate Consultant Oncology Pharmacist at the National Cancer Centre in Singapore, on how building new pharmacist-industry partnerships can drive an improvement in patient care.
| Speakers Biographies: | |
 | Amal Ismail Amal is the founder and Director of Care Pathway Solutions Practice at Double Helix Consulting based in London. Amal has over five years of consulting experience within the life sciences industry focused around global market access, patient pathway mapping and stakeholder engagement across a range of therapeutic areas. Amal qualified as a pharmacist in 2008 from Nottingham University, after which she obtained an MPhil in Bioscience Enterprise from Cambridge University (UK). |
 | Antoine Lecourt Antoine is currently Global Marketing Director of Oncology at GlaxoSmithKline (GSK). Antoine has over ten years of new product launch and brand development experience in the pharmaceutical industry with roles at GSK, Novartis, Pierre Fabre Oncologie and Roche. Antoine qualified as a pharmacist from Universite’ Paris Sud in 1999 and achieved a Masters in Marketing from HEC School of Management, Paris. |
 | Navin Joshi Navin is a Senior Director for GlaxoSmithKline (GSK) in Market Access Capability. Navin has over twenty years of experience in the pharmaceutical industry with roles at GSK and Merck in the areas of market access, NHS Affairs and Customer Solutions. Navin qualified as a pharmacist in 1988 with experience as a Senior Pharmacist at the National Hospitals, Queen Square, London. |
 | Dr. Alexandre Chan Professor Alexandre Chan is an Associate Professor with the Department of Pharmacy at National University of Singapore and an Associate Consultant Clinical Pharmacist at National Cancer Centre Singapore. Alex is also an Assistant Professor with the Department of Clinical Pharmacy at University of California San Francisco. Alex has published over 60 peer-reviewed manuscripts in oncology supportive care, anticancer drug-drug interactions and associated toxicities, and pharmaco-epidemiology and is currently Chair for ISOPP’s Education Committee and Board Member of the Multinational Association of Supportive Care in Cancer. |